StockData

Curis vs Inhibrx Biosciences

CRIS and INBX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRIS and INBX compare

Inhibrx Biosciences is the larger company, worth 964 times as much as Curis ($1.1B against $1.1M).

Curis scores higher on the StockData Score (7 against 1 for Inhibrx Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRISINBX
Size and price
Market cap$1.1M$1.1B
Share price$0.542$74.18
Change, 1 year−98.0%−6.3%
Change, 5 years−100.0%93.5%
Beta (5Y)−0.102.16
Employees24110
StockData Score
Total score7 (better)1
Valuation score3 (better)0
Growth score00
Performance score00
Health score4 (better)1
Dividend score00
Valuation
P/S0.3×–
P/B0.2×–
FCF yield–−12.2%
Fair value$6.75–
Margin of safety92.0%–
Growth
Revenue growth (TTM)−62.2%–
Revenue growth, 5Y average−2.7% (better)−36.8%
Profitability
Operating margin−203%–
Net margin−490%–
Financial health
Debt / equity0.00–
Interest coverage–−5.9×
Current ratio0.497.58 (better)
Altman Z-score−96.17−1.02 (better)
Piotroski F-score3 (better)1
Dividends and buybacks
Buyback yield−2171%–
Shareholder yield−2171%0.00% (better)
Ownership
Held by institutions32.1%97.4%
Held by insiders20.4%35.4%
Insider net buying, 12 months$5.5K$6.1M (better)
Superinvestors holding–1
Short interest, % of float61.8%35.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.